This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Jazz (JAZZ) delivered earnings and revenue surprises of -34.80% and -0.26%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y
by Zacks Equity Research
Axsome posts narrower second-quarter loss and 72% revenue surge, driven by strong Auvelity sales.
Sarepta Therapeutics (SRPT) to Report Q2 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q2 Earnings Expected to Decline
by Zacks Equity Research
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in ABCELLERA BIOLG (ABCL): Can Its 15.0% Jump Turn into More Strength?
by Zacks Equity Research
ABCELLERA BIOLG (ABCL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
ALKS Down Despite Positive Top-Line Data From Narcolepsy Study
by Zacks Equity Research
Alkermes falls 8.8% despite alixorexton hitting key goals in a narcolepsy type 1 study, as cataplexy data stirs investor concerns.
Here's Why Harmony Biosciences Is an Unconventional Cannabis Investment
by Sundeep Ganoria
HRMY isn't your typical cannabis play - its synthetic CBD gel targets rare brain disorders with no approved therapies.
Why Is Jazz (JAZZ) Up 7.9% Since Last Earnings Report?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Unlocking Jazz (JAZZ) International Revenues: Trends, Surprises, and Prospects
by Zacks Equity Research
Evaluate Jazz's (JAZZ) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Pharma Stock Roundup: NVO & JAZZ's Q1 Results, AZN's Pipeline Update
by Kinjel Shah
NVO and JAZZ report first-quarter results. AZN's asthma study on Breztri meets key goals.
Cannabis Stock Tilray Brands Loses 19% in a Month: Time to Sell or Hold?
by Sundeep Ganoria
TLRY's pivot into beverages shows promise, but with falling cannabis sales and delisting risks, we recommend staying on the sidelines for now.
JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook
by Zacks Equity Research
Jazz reports dismal first-quarter results. The company revises its 2025 EPS guidance to account for the recently completed Chimerix acquisition.
Here's What Key Metrics Tell Us About Jazz (JAZZ) Q1 Earnings
by Zacks Equity Research
Although the revenue and EPS for Jazz (JAZZ) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Jazz (JAZZ) delivered earnings and revenue surprises of -62.75% and 8.52%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y
by Zacks Equity Research
Axsome reports better-than-expected first quarter 2025 results. Net product revenues surge year over year on strong Auvelity sales.
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Illumina (ILMN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Buy, Sell or Hold JAZZ Stock? Key Tips Ahead of Q1 Earnings
by Sundeep Ganoria
Investors will likely focus on the sales performance of Jazz Pharmaceuticals' key neuroscience drugs, Xywav and Rylaze, when it reports Q1 results next week.
Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Unconventional Cannabis Stocks to Watch in 2025
by Sundeep Ganoria
Think cannabis investing is all hype? These three unconventional stocks could change your mind - and your portfolio - in 2025.
Buy 5 High ROE Stocks as Markets Break Tariff-Induced Losing Streak
by Supriyo Bose
CBOE, AGNC, JAZZ, AES and CNSWF are some of the stocks with high ROE to profit from as markets expect the tariff war to end soon.
Cardiol Therapeutics Stock: Is Cannabis Potential Priced In?
by Sundeep Ganoria
Cardiol Therapeutics shows promise with its CBD-based heart therapy, but a lack of approved drugs and a narrow pipeline raise red flags for cautious investors.
Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria
by Zacks Equity Research
The FDA approves SNY and REGN's Dupixent for treating chronic spontaneous urticaria, marking the seventh approved indication of the drug.
JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play?
by Sundeep Ganoria
Both JAZZ and HRMY expect sales from neuroscience products to grow in 2025.
JAZZ vs. ARGX: Which Stock Is the Better Value Option?
by Zacks Equity Research
JAZZ vs. ARGX: Which Stock Is the Better Value Option?